Parkinsons Disease Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Parkinson's Disease Therapeutics Market and it is segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), and Geography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market provides the value (in USD million) for the above segments.

Parkinsons Disease Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Parkinson's Disease Drugs Industry Overview

The Parkinson's disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of the global pharmaceutical firms are contributing to the dynamic nature of the market. Several new products are expected to be launched during the forecast period, which may lead to significant changes in the market shares of pharmaceutical firms that are currently active in the market. Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Pfizer Inc., and Novartis AG are some of the major players among others.drug

Parkinson's Disease Drugs Market Leaders

  1. GlaxoSmithKline PLC

  2. Boehringer Ingelheim International GmbH

  3. Newron Pharmaceuticals SPA

  4. F. Hoffmann-La Roche Ltd

  5. AbbVie Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Parkinson's Disease Drugs Market Concentration

Parkinson's Disease Drugs Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?